Literature DB >> 26573434

Epidemiology of myasthenia gravis in Ontario, Canada.

Ari Breiner1, Jessica Widdifield2, Hans D Katzberg3, Carolina Barnett3, Vera Bril3, Karen Tu4.   

Abstract

Incidence and prevalence estimates in myasthenia gravis have varied widely. Recent studies based on administrative health data have large sample sizes but lack rigorous validation of MG cases, and have not examined the North American population. Our aim was to explore trends in MG incidence and prevalence for the years 1996-2013 in the province of Ontario, Canada (population 13.5 million). We employed a previously validated algorithm to identify MG cases. Linking with census data allowed for the calculation of crude- and age/sex-standardized incidence and prevalence rates for the years 1996-2013. The regional distribution of MG cases throughout the province was examined. Mean age at the first myasthenia gravis encounter was 60.2 ± 17.1 years. In 2013, there were 3611 prevalent cases in Ontario, and the crude prevalence rate was 32.0/100,000 population. Age- and sex-standardized prevalence rates rose consistently over time from 16.3/100,000 (15.4-17.1) in 1996 to 26.3/100,000 (25.4-27.3) in 2013. Standardized incidence rates remained stable between 1996 (2.7/100,000; 95% CL 2.3-3.0) and 2013 (2.3/100,000; 2.1-2.6). Incidence was highest in younger women and older men, and geographic variation was evident throughout the province. In conclusion, this large epidemiological study shows rising myasthenia gravis prevalence with stable incidence over time, which is likely reflective of patients living longer, possibly due to improved disease treatment. Our findings provide accurate information on the Canadian epidemiology of myasthenia gravis and burden for health care resources planning for the province, respectively.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Administrative health data; Epidemiology; Incidence; Myasthenia gravis; Prevalence

Mesh:

Year:  2015        PMID: 26573434     DOI: 10.1016/j.nmd.2015.10.009

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  22 in total

1.  Epidemiology of paraneoplastic neurological syndromes: a population-based study.

Authors:  Alberto Vogrig; Gian Luigi Gigli; Samantha Segatti; Elisa Corazza; Alessandro Marini; Andrea Bernardini; Francesca Valent; Martina Fabris; Francesco Curcio; Francesco Brigo; Donatella Iacono; Paolo Passadore; Michele Rana; Jérôme Honnorat; Mariarosaria Valente
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

2.  Myasthenia gravis.

Authors:  Pierre R Bourque; Ari Breiner
Journal:  CMAJ       Date:  2018-09-24       Impact factor: 8.262

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Pulmonary Function Testing in Elderly Patients Treated for a Myasthenia Gravis Exacerbation.

Authors:  Stephen C van Gaal; Shane W English; Pierre R J Bourque; Jocelyn C Zwicker
Journal:  Neurohospitalist       Date:  2018-11-26

Review 5.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

6.  Anti-Muscle Specific Kinase (Anti-MuSK) Positive Myasthenia Gravis Overlapping With Parkinson's Disease: A Challenging Diagnosis.

Authors:  Mohammed S Albassam; Salman A Thabet; Mohammed Hmoud; Seraj Makkawi
Journal:  Cureus       Date:  2021-05-04

7.  Clinical delineation of myasthenia gravis in the Kingdom of Bahrain.

Authors:  Mohamed F Binfalah; Hussein H Alhafnawi; Ahmed A Jaradat; Eslam Shosha; Ali J Alhilly; Firas K Al Nidawi; Mariam M Alhammadi; Moiz O Bakhiet; Fatema M Abdulla
Journal:  Neurosciences (Riyadh)       Date:  2022-01       Impact factor: 0.735

8.  Celiac disease and risk of myasthenia gravis - nationwide population-based study.

Authors:  Sujata P Thawani; Thomas H Brannagan; Benjamin Lebwohl; Peter H R Green; Jonas F Ludvigsson
Journal:  BMC Neurol       Date:  2018-03-12       Impact factor: 2.474

9.  Familial aggregation of myasthenia gravis in affected families: a population-based study.

Authors:  Fu-Chao Liu; Chang-Fu Kuo; Lai-Chu See; Hsin-I Tsai; Huang-Ping Yu
Journal:  Clin Epidemiol       Date:  2017-11-02       Impact factor: 4.790

Review 10.  Update on ocular myasthenia gravis in Taiwan.

Authors:  Chao-Wen Lin; Ta-Ching Chen; Jieh-Ren Jou; Lin-Chung Woung
Journal:  Taiwan J Ophthalmol       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.